Protocol Compounds
6 Included
Protocol Evidence Audit
HIGH RISK
Target Indication:
Stage 4 Ovarian & Lung
Human Clinical Evidence:
0 / 6 Approved
CYP Metabolic Conflicts:
3 Severe Overlaps
Solvent / Carrier Danger:
DMSO Present
Safety & Pharmacokinetic Warnings
Ready for evaluation